{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-068757","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.828568+00:00","generated_at":"2026-06-27T00:49:21.911624+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Magenta Therapeutics reports Q4 2021 net loss $19.3M; first patient dosed in MGTA-117 trial","bullets":["Cash, cash equivalents and marketable securities at Dec 31, 2021: $176.9M, expected to fund operations into Q4 2023.","First patient dosed and completed initial safety assessment in Phase 1/2 trial of MGTA-117 targeted conditioning; data expected in 2022.","IND-enabling studies initiated for CD45-ADC; dose-ranging toxicology results anticipated in H2 2022.","MGTA-145 stem cell mobilization program advancing in sickle cell disease; data expected in H2 2022.","Net loss of $19.3M for Q4 2021 vs. $18.2M in Q4 2020; R&D expenses increased to $13.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-068757","json":"https://secwatch.observer/filing/0001193125-22-068757.json","markdown":"https://secwatch.observer/filing/0001193125-22-068757.md","text":"https://secwatch.observer/filing/0001193125-22-068757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522068757/0001193125-22-068757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522068757/d682941d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:49:21.911624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}